No abstract

Some categories of drugs are known for causing hyperglycemia or diabetes such as steroids, antipsychotics, and immunosuppressant. However, there has been little evidence from studies about the proportion of each drug in the context of drug-induced diabetes. In this study, we used data from the Japanese Adverse Drug Event Report (JADER) database, a spontaneous reporting system database maintained at the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan, reported between April 2004 and June 2017. Among 459,250 reports of adverse drug reactions in JADER database, reported instances of the adverse event of hyperglycemia or diabetes were extracted. After the exclusion of anti-diabetes drugs, the drugs frequently implicated in the development of hyperglycemia or diabetes, including prednisolone, tacrolimus, everolimus, ribavirin, quetiapine, aripiprazole, interferon alfa-2b, risperidone, atorvastatin, dexamethasone, ciclosporin, nilotinib, methylprednisolone, or nivolumab, were identified. Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, was manifested as the third most frequently associated drug with hyperglycemia or diabetes (340 cases), following prednisolone (694 cases) and tacrolimus (393 cases), and the reporting odds ratio (ROR 8.56, 95% CI 7.65-9.57) of this drug was higher than that of the two aforementioned drugs (ROR 3.96,). These results suggest that there is a potent association of evelolimus with hyperglycemia in clinical practice in Japan.

Introduction: Dulaglutide is a long-acting glucagon-like peptide 1 receptor agonist that is administered once weekly for the treatment of type 2 diabetes. However, the immediate glucose-lowering effect of dulaglutide after the first administration and the factors affecting the efficacy of the drug remain unclear. Methods: This study was a retrospective and observational study of 80 subjects with type 2 diabetes conducted in a hospitalized setting. The changes (D) in the blood glucose (BG) levels at six time points (6-point BG levels) from the baseline (day -1) to the day after the first administration of 0.75 mg of dulaglutide (day 1) were evaluated. The associations of the D 6point BG levels with the patients' characteristics and laboratory data were also analyzed. Results: Significant reduction of the fasting BG, preprandial BG, postprandial BG, and standard deviation (SD) of the 6-point BG levels was

Aims/Introduction This study aimed to clarify the nature of the relationship between the abdominal aortic calcification (AAC) grade and the presence of cardiovascular diseases, and determine factors related to AAC grade in people with type 2 diabetes mellitus. Materials and Methods This retrospective cross‐sectional study enrolled 264 inpatients with type 2 diabetes mellitus. The AAC score and length were measured using the lateral abdominal radiographs. Logistic regression models were used to assess the associations between AAC scores/lengths and the presence of coronary artery disease (CAD), cerebral infarction (CI) and peripheral artery disease (PAD). The correlation between AAC scores/lengths and other clinical factors were evaluated using linear regression models. Results The AAC score was significantly correlated with prevalent CAD and CI independent of age and smoking, but not with the prevalence of PAD. AAC length was not significantly correlated with the presence of CAD, CI or PAD; however, the sample size was insufficient to conclude, probably due to low prevalence. Both the AAC score and length were correlated inversely with body mass index (BMI) and, with the Fibrosis‐4 (Fib‐4) index >2.67; these correlations were significant after adjusting for cardiovascular risk factors and BMI, although AAC was not associated with ultrasonography‐diagnosed fatty liver. There was a significant interaction between BMI and Fib‐4 index; lower BMI and Fib‐4 index >2.67 showed a synergistic association with high AAC grade. Conclusions AAC score is associated with CAD and CI morbidity in participants with type 2 diabetes mellitus. Low BMI and Fib‐4 index >2.67 can be valuable indicators of AAC in people with type 2 diabetes mellitus.

Background: Little is known about the association between abdominal aortic calcification (AAC) and the risk of cardiovascular disease (CVD) among patients with diabetes. This study evaluated the cross-sectional association between AAC and CVD morbidity in patients with type 2 diabetes. Methods: This retrospective cross-sectional study enrolled 285 inpatients with type 2 diabetes. The lateral view of an abdominal X-ray image obtained while each subject was in a standing position was examined, and the AAC score and AAC length, corresponding to the area of calcific deposits in the anterior and posterior aortic wall for the L1-4 and L1-5 regions, respectively, were measured. The associations between the AAC scores and lengths and the presence of coronary artery disease (CAD), cerebral infarction (CI), and peripheral artery disease (PAD) were then assessed. The correlation between the AAC grades and other clinical factors were also evaluated. Results: The degree of AAC was significantly correlated with a higher prevalence of CAD and CI but not PAD after adjustments for cardiovascular risk factors. The AAC score was inversely correlated with BMI, and both the AAC score and the AAC length were correlated with the Fib-4 index; these correlations persisted after adjustments for cardiovascular risk factors and BMI, although AAC was not associated with ultrasonography-diagnosed fatty liver. Conclusion: AAC is associated with CAD and CI morbidity in patients with type 2 diabetes. AAC grading also predicts the Fib-4 index, a hepatic fibrosis marker, suggesting a novel potential predictor of liver disease that is independent of cardiovascular risk factors and obesity.